SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
ENVB reported Third Quarter 2026 results. The price and volatility reaction is pending.
ENVBearnings

Earnings reactions, page 2

Enveric Biosciences (ENVB) Q3 FY2026 earnings

November 14, 2026 · SharpeIQ Research Desk

Reported results

  • Net loss attributable to stockholders was $2.5 million for the third quarter ended September 30, 2026, compared to $3.4 million for the quarter ended September 30, 2025.
  • Basic and diluted loss per share was $0.57 for the third quarter ended September 30, 2026, compared to $10.81 for the quarter ended September 30, 2025.
  • Net loss for the third quarter ended September 30, 2026 included $0.2 million in net non-cash expense.
  • Cash-on-hand was $5.6 million as of September 30, 2026.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-13 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →